| Name | Title | Contact Details |
|---|---|---|
Jennifer Wear |
AVP of Product Marketing | Profile |
Spencer Korn |
Senior Vice President of Sales | Profile |
Ashley Ratcliff |
Director, People and Culture Communications | Profile |
Amit Pandya |
VP, Talent | Profile |
Manami Kunz |
Director, Customer Success | Profile |
Stephenville Medical and Surgical Clinic is a Stephenville, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TriRivers Health Partners is a Rockford, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Founded in 1986, eQHealth Solutions is a population health management and technology solutions company that touches millions of lives annually throughout the nation. Our high-tech and high-touch models include innovative technology solutions and care coordination services, and focus on outcomes and optimization of provider and payer networks. eQHealth serves a variety of entities including federal, state and commercial clients.
We’re creative and passionate professionals on a mission – to deliver top-notch natural health products to a global community. 🍃💪
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.